ALK and non-small cell lung carcinoma: Moreover, MPE-derived NSCLC cell lines with EML4-ALK fusion and its targeted drugs including crizotinib, alectinib, and ceritinib were grouped as well (Fig. 5A and Supplementary Table 5).